4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF

1 . A compound of Formula XI-B

wherein R 36 is selected from H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 2 -C 4 alkenyl, substituted or unsubstituted heteroaryl, and C 3 -C 6 cycloalkyl;

R 37 is substituted or unsubstituted C 2 -C 4 alkenyl or substituted or unsubstituted C 2 -C 4 alkynyl;

R 38 is selected from substituted or unsubstituted nitrogen containing 5-membered heteroaryl, substituted or unsubstituted nitrogen containing 5- or 6- membered partially unsaturated heterocyclyl and substituted or unsubstituted nitrogen containing 6-10 membered heteroaryl;

R 44 is one or more substituents selected from H, halo, alkoxy and hydroxy; and

R 45 is one or more substituents selected from H, D and alkyl;

provided R 38 is not 4-pyridyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 wherein R 36 is selected from H, halo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl and C 3 -C 6 cycloalkyl; R 37 is substituted or unsubstituted C 2 -C 4 alkenyl or substituted or unsubstituted C 2 -C 4 alkynyl; R 38 is selected from substituted or unsubstituted nitrogen containing 5-membered heteroaryl, substituted or unsubstituted nitrogen containing 5- or 6- membered partially unsaturated heterocyclyl and substituted or unsubstituted nitrogen containing 6-10 membered heteroaryl; R 44 is one or more substituents selected from H, alkoxy and hydroxy; and R 45 is H; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 wherein R 38 is selected from substituted or unsubstituted nitrogen containing 5-membered heteroaryl selected from pyrazolyl, isoxazolyl, isothiazolyl, pyrrolyl, thiazolyl, triazolyl and imidazolyl; substituted or unsubstituted nitrogen containing 6- membered heteroaryl selected from pyridinyl, pyrimidinyl and pyrazinyl; substituted or unsubstituted nitrogen containing 5-membered partially unsaturated heterocyclyl selected from pyrrolinyl, and imidazolidinyl; and substituted or unsubstituted dihydropyridinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 wherein R 36 is selected from H, chloro, methyl, ethyl, isopropyl, ethenyl, allylyl, trifluoromethyl, furyl, pyridyl and cyclopropyl; and R 38 is selected from substituted 5-pyrazolyl, substituted 4-pyrazolyl, substituted 1-pyrazolyl, substituted or unsubstituted 4-isoxazolyl, substituted or unsubstituted 4-isothiazolyl, substituted or unsubstituted 3-pyrrolyl, substituted or unsubstituted 5-thiazolyl, substituted or unsubstituted 5-imidazolyl, substituted or unsubstituted 1-imidazolyl, substituted or unsubstituted [1,2,4]triazol-5-yl, substituted or unsubstituted 3-pyridyl, and substituted or unsubstituted 5-pyrimidinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 wherein R 36 is chloro, methyl, ethyl, isopropyl, allylyl or cyclopropyl; and R 38 is selected from substituted 5-pyrazolyl, substituted 4-pyrazolyl, substituted 1-pyrazolyl, substituted or unsubstituted 4-isoxazolyl, substituted or unsubstituted 4-isothiazolyl, substituted or unsubstituted 3-pyrrolyl, substituted or unsubstituted 5-thiazolyl, substituted or unsubstituted 5-imidazolyl, substituted or unsubstituted 1-imidazolyl, substituted or unsubstituted [1,2,4]triazol-5-yl, substituted or unsubstituted 3-pyridyl, and substituted or unsubstituted 5-pyrimidinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

6 . The compound of claim 1 wherein R 38 is 3-trifluoromethyl-pyrazol-4-yl, 1-isopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl, 1-ethyl-3-trifluoromethyl-pyrazol-4-yl, 1,3-diethyl-pyrazol-4-yl, 1-methyl-3-difluoromethyl-pyrazol-4-yl, 1-(d 3 -methyl)-3-difluoromethyl-pyrazol-4-yl, 1-butyl-3-trifluoromethyl-pyrazol-4-yl, 1-methoxymethyl-3-trifluoromethyl-pyrazol-4-yl, 1-propyl-3-trifluoromethyl-pyrazol-4-yl, 1,3-dimethyl-pyrazol-4-yl, 1,3,5-trimethyl-pyrazol-4-yl, 1-methyl-3-cyclopropyl-pyrazol-4-yl, 1-ethyl-3-cyclopropyl-pyrazol-4-yl, 1-methyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-3-amino-pyrazol-4-yl, 1-ethyl-3-methoxy-pyrazol-4-yl, 1-hydroxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-[2-hydroxypropyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[2-hydroxyisobutyl]-3-trifluoromethyl-pyrazol-4-yl, 1-methoxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminoethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N-methylaminocarbonylmethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N-methylaminocarbonylethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminocarbonylmethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylmethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methylcarbonylaminoethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methylcarbonylaminobutyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylethyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylpropyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylisopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-cyanomethyl-3-trifluoromethyl-pyrazol-4-yl, 1-cyanoethyl-3-trifluoromethyl-pyrazol-4-yl, 1-cyanopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminocarbonylethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-carboxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-carboxymethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methoxycarbonylmethyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-3-carboxy-pyrazol-4-yl, 1-ethyl-5-carboxy-pyrazol-4-yl, 1-ethyl-3-methylaminocarbonyl-pyrazol-4-yl, 1-ethyl-3-[N,N-dimethylaminocarbonyl]-pyrazol-4-yl, 1-ethyl-5-methylaminocarbonyl-pyrazol-4-yl, 1-ethyl-5-[N,N-dimethylaminocarbonyl]-pyrazol-4-yl, 1-benzyl-3-methyl-pyrazol-4-yl, 1-(cyclopropylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-cyclopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylazetidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpyrrolidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpiperidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpiperidin-4-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-(4-pyridinyl)-3-trifluoromethyl-pyrazol-4-yl, 1-(3-chloropyridin-4-yl)-3-trifluoromethyl-pyrazol-4-yl, 1-(3,5-difluoropyridin-4-yl)-3-trifluoromethyl-pyrazol-4-yl, 1-(3-pyridinylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-(2-pyridinylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-(5-oxadiazolylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-(4-oxazolylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-(3-pyridinylmethyl)-3-methyl-pyrazol-4-yl, 1-(2-pyridinylmethyl)-3-methyl-pyrazol-4-yl, 1-[2-pyridyl]-3-methyl-pyrazol-4-yl, 1-methyl-5-pyrazolyl, 1-ethyl-5-trifluoromethylpyrazol-4-yl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-3-cyclopropyl-pyrazol-5-yl, 1-methyl-4-pyrazolyl, 1-ethyl-3-methylpyrazol-4-yl, 1,5-dimethyl-4-pyrazolyl, 1,3,5-trimethyl-4-pyrazolyl, 1-ethyl-3-trifluoromethyl-5 methyl-pyrazol-4-yl, 1-methyl-3-pyrazolyl, 4-methyl-3-pyrazolyl, 1-methyl-[1,2,4]triazol-3-yl, 4-bromo-2-methyl-[1,2,4]triazol-5-yl, 4-bromo-2-ethyl-[1,2,4]triazol-5-yl, 1-methyl-[1,2,4]triazol-5-yl, 4-isothiazolyl, 4-methyl-2-oxazolyl, isoxazol-4-yl, 2,4-dimethylthiazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2-methyl-5-thiazolyl or 4-methyl-5-thiazolyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 wherein R 38 is 3-trifluoromethyl-pyrazol-4-yl, 1-isopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methyl-3-difluoromethyl-pyrazol-4-yl, 1-butyl-3-trifluoromethyl-pyrazol-4-yl, 1-methoxymethyl-3-trifluoromethyl-pyrazol-4-yl, 1-propyl-3-trifluoromethyl-pyrazol-4-yl, 1,3-dimethyl-pyrazol-4-yl, 1,3,5-trimethyl-pyrazol-4-yl, 1-methyl-3-cyclopropyl-pyrazol-4-yl, 1-methyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-3-amino-pyrazol-4-yl, 1-ethyl-3-methoxy-pyrazol-4-yl, 1-hydroxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-[2-hydroxypropyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[2-hydroxyisobutyl]-3-trifluoromethyl-pyrazol-4-yl, 1-methoxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminoethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N-methylaminocarbonylmethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N-methylaminocarbonylethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminocarbonylmethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylmethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methylcarbonylaminoethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methylcarbonylaminobutyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylethyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylpropyl-3-trifluoromethyl-pyrazol-4-yl, 1-aminocarbonylisopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-cyanopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-[N,N-dimethylaminocarbonylethyl]-3-trifluoromethyl-pyrazol-4-yl, 1-carboxyethyl-3-trifluoromethyl-pyrazol-4-yl, 1-carboxymethyl-3-trifluoromethyl-pyrazol-4-yl, 1-methoxycarbonylmethyl-3-trifluoromethyl-pyrazol-4-yl, 1-ethyl-3-carboxy-pyrazol-4-yl, 1-ethyl-5-carboxy-pyrazol-4-yl, 1-ethyl-3-methylaminocarbonyl-pyrazol-4-yl, 1-ethyl-3-[N,N-dimethylaminocarbonyl]-pyrazol-4-yl, 1-ethyl-5-methylaminocarbonyl-pyrazol-4-yl, 1-ethyl-5-[N,N-dimethylaminocarbonyl]-pyrazol-4-yl, 1-benzyl-3-methyl-pyrazol-4-yl, 1-(cyclopropylmethyl)-3-trifluoromethyl-pyrazol-4-yl, 1-cyclopropyl-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylazetidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpyrrolidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpiperidin-3-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-[1-methylpiperidin-4-yl]-3-trifluoromethyl-pyrazol-4-yl, 1-(3-pyridinylmethyl)-3-methyl-pyrazol-4-yl, 1-(2-pyridinylmethyl)-3-methyl-pyrazol-4-yl, 1-[2-pyridyl]-3-methyl-pyrazol-4-yl, 1-methyl-5-pyrazolyl, 1-ethyl-5-trifluoromethylpyrazol-4-yl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-3-cyclopropyl-pyrazol-5-yl, 1-methyl-4-pyrazolyl, 1-ethyl-3-methylpyrazol-4-yl, 1,5-dimethyl-4-pyrazolyl, 1,3,5-trimethyl-4-pyrazolyl, 1-methyl-3-pyrazolyl, 4-methyl-3-pyrazolyl, 1-methyl-[1,2,4]triazol-3-yl, 4-bromo-2-methyl-[1,2,4]triazol-5-yl, 4-bromo-2-ethyl-[1,2,4]triazol-5-yl, 1-methyl-[1,2,4]triazol-5-yl, 4-isothiazolyl, 4-methyl-2-oxazolyl, isoxazol-4-yl, 2,4-dimethylthiazol-5-yl, 3,5-dimethylisoxazol-4-yl, 2-methyl-5-thiazolyl or 4-methyl-5-thiazolyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 wherein R 38 is 5-pyrimidinyl, 2-methyl-5-pyrimidinyl, 4-methyl-5-pyrimidinyl, 4,6-dimethoxy-5-pyrimidinyl, 4,6-dimethyl-5-pyrimidinyl, 4-triflouromethyl-5-pyrimidinyl, 4-pyrimidinyl, 2-methyl-4-pyrimidinyl, 4-methyl-6-pyrimidinyl, 2,4-dimethyl-6-pyrimidinyl, 3-pyridinyl, 2-pyridinyl, 4-methyl-2-pyridinyl, 2-triflouromethyl-3-pyridinyl, 4-triflouromethyl-3-pyridinyl, 2-methyl-3-pyridinyl, 2,5-dimethyl-3-pyridinyl, 2,6-dimethyl-3-pyridinyl, 2,4-dimethyl-3-pyridinyl, 2-ethyl-3-pyridinyl, 5-methyl-3-pyridinyl, 2-ethoxy-3-pyridinyl, 2-ethoxy-5-methyl-3-pyridinyl, 2-methoxy-3-pyridinyl, 2-methoxy-6-methyl-3-pyridinyl, 2-ethoxy-6-methyl-3-pyridinyl, 2-isopropoxy-3-pyridinyl, 2-(3-pentoxy)-3-pyridinyl, 2-methoxyethoxy-3-pyridinyl, 2-cyclopropoxy-3-pyridinyl, 2-cyclopentyloxy-3-pyridinyl, 2-cyclohexloxy-3-pyridinyl, 2-fluoro-3-pyridinyl, 2-chloro-3-pyridinyl, 2-phenyl-3-pyridinyl, 2-flouro-3-methyl-5-pyridinyl, 2-flouro-3-chloro-5-pyridinyl, 3-fluoro-5-pyridinyl, 3-chloro-5-pyridinyl, 2-chloro-4-methyl-5-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-5-pyridinyl, 2-ethoxy-5-pyridinyl, 3-ethoxy-5-pyridinyl, 3-triflouromethyl-5-pyridinyl, 3-ethyl-5-pyridinyl, 2,3-dimethyl-5-pyridinyl, 2-(2-hydroxymethylpyrrolidin-1-yl)-5-pyridinyl, 2-(morpholin-1-yl)-3-chloro-5-pyridinyl, 2-(dimethylaminoethoxy)-5-pyridinyl, 2-(2-dimethylaminomethylpyrrolidin-1-yl)-5-pyridinyl, 2-phenyl-5-pyridinyl, 2-methyl-6-pyridinyl, 2,4-dimethyl-6-pyridinyl or 2-ethyl-6-pyridinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 wherein R 38 is selected from substituted or unsubstituted tetrahydroquinolinyl; substituted or unsubstituted 1-pyrrolin-3-yl, substituted or unsubstituted 1-imidazolidinyl, and substituted or unsubstituted dihydropyridin-3-yl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 1 wherein R 38 is selected from 1-methoxy-4-isoquinolinyl, 1-chloro-4-isoquinolinyl, 6-methyl-4-isoquinolinyl, 1-oxo-2-methyl-4-isoquinolinyl, 5-pyrrolopyridinyl, [1,3,3a]-triazainden-5-yl, 1-ethyl-3-pyrrolopyridinyl, 1-methyl-5-pyrrolopyridinyl, 3-quinolinyl, 4-isoquinolinyl and 4-quinolinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

11 . The compound of claim 1 wherein R 37 is ethenyl, fluoroethenyl, propenyl, fluoropropenyl, propynyl, dialkylaminopropenyl, alkylaminopropenyl, aminopropenyl or nitrogen-containing heterocyclyl-propenyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

12 . The compound of claim 1 selected from

empty

Blank

or a pharmaceutically acceptable salt thereof.

13 . A compound of Formula XII

wherein R 36 is halo or C 1-6 alkyl;

R 37 is C 2 -C 4 alkenyl; and

R 39 is H, halo, C 1-6 alkyl, cyano, substituted or unsubstituted cycloalkyl, substituted or unsubstituted nitrogen containing 5- or 6- membered partially unsaturated heterocyclyl or substituted or unsubstituted 5-10- membered heteroaryl; or an isomer or a stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 13 wherein R 36 is chloro or methyl; R 37 is ethenyl; and R 39 is selected from H, bromo, chloro, C 1-4 alkyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted pyridyl, and substituted or unsubstituted isoquinolinyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 13 wherein R 39 is selected from H, bromo, chloro, methyl, cyano, isoquinoline-4-yl, 1,3-dimethylpyrazol-4-yl, 3,5-dimethylisoxazol-4-yl and 2-chloro-3-pyridyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

16 . The compound of claim 13 selected from

or a pharmaceutically acceptable salt thereof.

17 . A compound of Formula XIV

wherein R 36 is selected from H, halo, C 1 -C 4 alkyl, C 2 -C 4 alkenyl and C 3 -C 6 cycloalkyl;

R 37 is substituted or unsubstituted C 2 -C 4 alkenyl, or substituted or unsubstituted C 2 -C 4 alkynyl;

R 41 is selected from H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkoxyalkyl, C 1-6 alkylamino-C 1-6 alkyl, C 1-6 alkylaminocarbonyl-C 1-6 alkyl, aminocarbonyl-C 1-6 alkyl, C 1-6 alkoxycarbonyl-C 1-6 alkyl, carboxy-C 1-6 alkyl, C 1-6 alkylcarbonylamino-C 1-6 alkyl, C 1-6 cyanoalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkyl, aryl-C 1-6 alkyl, 5 or 6 membered heteroaryl-C 1-6 alkyl, 5 or 6 membered heterocyclyl and 5 or 6 membered heteroaryl;

R 42 is selected from H, carboxy, amino, C 1-6 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, and C 3-6 cycloalkyl;

R 43 is selected from H, carboxy, C 1-4 alkyl, C 1-3 haloalkyl, and C 1-6 alkylaminocarbonyl; and

R 44 is one or more substituents selected from H, halo, alkoxy and hydroxy; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

18 . The compound of claim 17 wherein R 41 is selected from H, ethyl, isopropyl, butyl, propyl, methyl, 1-hydroxyethyl, 2-hydroxymethylethyl, 1-hydroxy-2,2-dimethylethyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl, methoxymethyl, methoxyethyl, dimethylaminoethyl, carboxymethyl, carboxyethyl, methoxycarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminocarbonylethyl, methylaminocarbonylethyl, methylaminocarbonylmethyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonyl-1,1-dimethylmethyl, methylcarbonylaminoethyl, 1-methylcarbonylamino-2.2-dimethylethyl, 2-cyano-2-methylethyl, cyclopropyl, cyclopropylmethyl, benzyl, 3-pyridinylmethyl, 2-pyridinylmethyl, 1-methylazetidin-3-yl, 1-methylpyrrolidin-3-yl, 1-methylpiperidin-4-yl, 1-methylpiperidin-3-yl and 2-pyridyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

19 . The compound of claim 17 wherein R 37 is selected from ethenyl, fluoroethenyl, propynyl, dialkylaminopropenyl, alkylaminopropenyl, aminopropenyl and nitrogen-containing heterocyclyl-propenyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

20 . The compound of claim 17 wherein R 37 is dimethylaminopropenyl, methylaminopropenyl, or aminopropenyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

21 . The compound of claim 17 wherein R 36 is selected from H, chloro, methyl, ethyl, isopropyl, allylyl, and cyclopropyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

22 . The compound of claim 17 wherein R 42 is selected from H, trifluoromethyl, difluoromethyl, methyl, methoxy, amino, dimethylamino, carboxy. methylaminocarbonyl, dimethylaminocarbonyl, and cyclopropyl; or an isomer or a pharmaceutically acceptable salt thereof.

23 . The compound of claim 17 wherein R 43 is selected from H, trifluoromethyl, methyl, carboxy, and methylaminocarbonyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

24 . The compound of claim 17 wherein R 44 is one or more substituents selected from H, hydroxy, fluoro and methoxy; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

25 . A compound of Formula XV

wherein R 36 is selected from H, halo, C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, C 2 -C 4 alkenyl, substituted or unsubstituted 5-6 membered heteroaryl and C 3 -C 6 cycloalkyl;

R 37 is substituted or unsubstituted C 2 -C 4 alkenyl, or substituted or unsubstituted C 2 -C 4 alkynyl;

R 41 is selected from H, C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkoxyalkyl, C 1-6 alkylamino-C 1-6 alkyl, C 1-6 alkylaminocarbonyl-C 1-6 alkyl, aminocarbonyl-C 1-6 alkyl, C 1-6 alkoxycarbonyl-C 1-6 alkyl, carboxy-C 1-6 alkyl, C 1-6 alkylcarbonylamino-C 1-6 alkyl, C 1-6 cyanoalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkyl, aryl-C 1-6 alkyl, substituted or unsubstituted 5 or 6 membered heteroaryl-C 1-6 alkyl, substituted or unsubstituted 5 or 6 membered heterocyclyl and substituted or unsubstituted 5 or 6 membered heteroaryl;

R 42 is selected from H, carboxy, amino, C 1-6 alkyl, C 1-3 haloalkyl, C 1-6 alkoxy, C 1-6 alkylamino, C 1-6 alkylaminocarbonyl, and C 3-6 cycloalkyl;

R 43 is selected from H, carboxy, cyano, C 1-4 alkyl, C 1-3 haloalkyl, and C 1-6 alkylaminocarbonyl;

R 44 is H, halo, hydroxy or C 1-6 alkoxy; and

R 45 is one or more substituents selected from H, D or C 1-4 alkyl;

or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

26 . The compound of claim 25 wherein R 41 is selected from H, ethyl, isopropyl, butyl, propyl, methyl, D 3 -methyl, 1-hydroxyethyl, 2-hydroxymethylethyl, 1-hydroxy-2,2-dimethylethyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl, methoxymethyl, methoxyethyl, dimethylaminoethyl, carboxymethyl, carboxyethyl, methoxycarbonylmethyl, dimethylaminocarbonylmethyl, dimethylaminocarbonylethyl, methylaminocarbonylethyl, methylaminocarbonylmethyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonyl-1,1-dimethylmethyl, methylcarbonylaminoethyl, 1-methylcarbonylamino-2.2-dimethylethyl, 2-cyano-2-methylethyl, cyanomethyl, cyanoethyl, cyclopropyl, cyclopropylmethyl, benzyl, 3-pyridinylmethyl, 2-pyridinylmethyl, 4-oxazolylmethyl, oxadiazol-5-ylmethyl, 1-methylazetidin-3-yl, 1-methylpyrrolidin-3-yl, 1-methylpiperidin-4-yl, 1-methylpiperidin-3-yl, 3,5-difluoro-4-pyridyl, 3-chloro-4-pyridyl, 4-pyridyl and 2-pyridyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

27 . The compound of claim 25 wherein R 36 is selected from H, chloro, methyl, ethyl, isopropyl, propenyl, trifluoromethyl, 2-furyl, 2-pyridinyl, and cyclopropyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

28 . The compound of claim 25 wherein R 37 is selected from ethenyl, fluoroethenyl, fluoropropenyl, propynyl, dialkylaminopropenyl, alkylaminopropenyl, aminopropenyl, substituted or unsubstituted 3-7 membered nitrogen-containing heterocyclyl-ethenyl and substituted or unsubstituted 3-7 membered nitrogen-containing heterocyclyl-propenyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

29 . The compound of claim 25 wherein R 37 is selected from azetidin-1-ylpropenyl, 1-methylpyrrolidin-2-ylethenyl, dimethylaminopropenyl, methylaminopropenyl, piperidin-1-ylpropenyl, 4-hydroxy-piperidin-1-ylpropenyl, pyrrolidin-1-ylpropenyl, 3-hydroxypyrrolidin-1-ylpropenyl, morpholin-1-ylpropenyl, and aminopropenyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

30 . The compound of claim 25 wherein R 42 is selected from H, trifluoromethyl, difluoromethyl, methyl, ethyl, methoxy, amino, dimethylamino, carboxy. methylaminocarbonyl, dimethylaminocarbonyl, and cyclopropyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

31 . The compound of claim 25 wherein R 43 is selected from H, trifluoromethyl, methyl, ethyl, carboxy, cyano and methylaminocarbonyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

32 . The compound of claim 25 wherein R 44 is one or more substituents selected from H, fluoro, hydroxy and methoxy; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

33 . The compound of claim 25 wherein R 45 is one or more substituents selected from H, D, and methyl; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

34 . The compound of claim 25 wherein R 45 is H; or an isomer or stereoisomer of any of the foregoing, or a mixture thereof or a pharmaceutically acceptable salt thereof.

35 . The compound of claim 25 selected from

Blank

Blank

or a pharmaceutically acceptable salt thereof.

36 . A pharmaceutical composition, comprising the compound of any one of claims 1-35 or the pharmaceutically acceptable salt thereof and at least one carrier, excipient, or diluent.

37 . A method of inhibiting E1 in a subject in need thereof, said method comprising administering to said subject a pharmaceutically acceptable excipient and a therapeutically effective amount of the compound of any one of claims 1-35 or the pharmaceutical composition according to claim 36 .

38 . A method of treating cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of the compound of any one of claims 1-35 or the pharmaceutical composition according to claim 36 .

39 . A method of inhibiting cell proliferation in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of the compound of any one of claims 1-35 or the pharmaceutical composition according to claim 36 .

40 . The method of claim 39 wherein the cancer is selected from acute myeloid leukemia, large B-cell lymphoma, lung squamous cell carcinoma, pancreatic adenocarcoma, esophegeal carcinoma, cervical squamous cell carcinoma, endocervical adenocarcoma, stomach adenocarcinomathymoma, renal cell carcinoma, head and neck squamous cell carcinoma, bladder carcinoma, ovarian cystadenocarcinoma and mesothelioma.

41 . Use of the compound of any one of claims 1-35 , or the pharmaceutical composition according to claim 36 , in the manufacture of a medicament for treating an E1 related disease.

42 . The compound of any one of claims 1-35 , or the pharmaceutical composition according to claim 36 , for use in treating an E1 related disease.

43 . A medicament for treating an E1 related disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 1-35 , or the pharmaceutical composition according to claim 36 .

44 . The use of claim 41 wherein the E1 related disease is selected from acute myeloid leukemia, large B-cell lymphoma, lung squamous cell carcinoma, pancreatic adenocarcoma, esophegeal carcinoma, cervical squamous cell carcinoma, endocervical adenocarcoma, stomach adenocarcinomathymoma, renal cell carcinoma, head and neck squamous cell carcinoma, bladder carcinoma, ovarian cystadenocarcinoma and mesothelioma.

45 . The medicament of claim 43 wherein the E1 related disease is selected from acute myeloid leukemia, large B-cell lymphoma, lung squamous cell carcinoma, pancreatic adenocarcoma, esophegeal carcinoma, cervical squamous cell carcinoma, endocervical adenocarcoma, stomach adenocarcinomathymoma, renal cell carcinoma, head and neck squamous cell carcinoma, bladder carcinoma, ovarian cystadenocarcinoma and mesothelioma.

46 . The compound of claim 42 wherein the E1 related disease is selected from acute myeloid leukemia, large B-cell lymphoma, lung squamous cell carcinoma, pancreatic adenocarcoma, esophegeal carcinoma, cervical squamous cell carcinoma, endocervical adenocarcoma, stomach adenocarcinomathymoma, renal cell carcinoma, head and neck squamous cell carcinoma, bladder carcinoma, ovarian cystadenocarcinoma and mesothelioma.